Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024 02:06 ET
|
Zealand Pharma
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to...
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
February 20, 2024 02:00 ET
|
Zealand Pharma
Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand...
Total number of shares and voting rights in Zealand Pharma at January 31, 2024
January 31, 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma major shareholder announcement: Van Herk Investments
January 26, 2024 12:00 ET
|
Zealand Pharma
Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 19, 2024 11:30 ET
|
Zealand Pharma
Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL)...
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 17, 2024 10:30 ET
|
Zealand Pharma
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
Zealand Pharma completes registration of capital increase
January 12, 2024 05:00 ET
|
Zealand Pharma
Company announcement – No. 3 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
January 10, 2024 11:15 ET
|
Zealand Pharma
Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
January 08, 2024 15:45 ET
|
Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
January 02, 2024 02:00 ET
|
Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...